Skip to content

Cart

Your cart is empty

Continue shopping
India's Clinical Research Expansion Moves Beyond Its Major Cities
Nov 19, 20264 min read

India's Clinical Research Expansion Moves Beyond Its Major Cities

India has long been an important part of the global pharmaceutical industry, particularly in the manufacturing and supply of medicines. Now, the country is investing in another critical part of pharmaceutical development: the clinical research infrastructure needed to bring new treatments to patients.

On 14 October 2026, AstraZeneca India and the National Institute of Pharmaceutical Education and Research (NIPER) Raebareli announced a collaboration to strengthen clinical trial capabilities across 25 emerging research locations. The initiative aims to extend India's clinical research network beyond its major metropolitan centres, creating new opportunities for researchers, healthcare institutions and patients across the country. [1]

The announcement forms part of a much larger ambition. Under its Biopharma SHAKTI initiative, India is working towards a nationwide network of more than 1,000 accredited clinical trial sites, supported by investment in research infrastructure, specialist training and pharmaceutical innovation. [2]

For a country already recognised as one of the world's largest pharmaceutical producers, this represents an important opportunity to strengthen its contribution to the development of new medicines.

Bringing clinical research closer to patients

Clinical trials have traditionally been concentrated around major hospitals, research institutions and metropolitan centres. These established facilities provide access to experienced researchers, specialist equipment and the infrastructure required to conduct complex studies.

Expanding that network into additional regions could make participation more accessible to patients who would otherwise need to travel considerable distances to reach a research centre.

It also creates opportunities to involve more geographically diverse patient populations in clinical studies. This is particularly relevant as pharmaceutical research increasingly focuses on complex diseases, personalised treatments and therapies that may benefit from broader clinical evidence.

For international pharmaceutical companies, a larger network of suitably qualified research sites could provide access to new patient populations and additional clinical expertise. For India, it offers an opportunity to develop research capabilities across more communities while strengthening the country's role in global drug development.

Building the expertise to support expansion

The AstraZeneca and NIPER Raebareli partnership focuses on more than establishing additional research locations.

Its first phase will assess the capabilities of 25 clinical trial sites, providing targeted training, mentoring and support to strengthen their readiness for future studies. This includes improving clinical research documentation, ethical oversight, safety procedures and trial feasibility processes.

AstraZeneca India will contribute clinical development expertise, while NIPER Raebareli will support workforce development through structured training and certification. The collaboration brings together government, academic and industry expertise, creating a model that could eventually be extended to additional locations and therapeutic areas. [1]

This focus on professional development is especially significant. Well-trained research teams, consistent procedures and reliable clinical data are essential to conducting studies that meet international expectations.

By investing in these capabilities alongside physical infrastructure, India has an opportunity to establish a more extensive and sustainable research network.

A wider investment in pharmaceutical innovation

The initiative also reflects a broader shift in India's pharmaceutical ambitions.

The country's 2026-27 Union Budget proposed ₹10,000 crore in investment over five years through Biopharma SHAKTI, a programme designed to strengthen domestic capabilities in biologics, biosimilars and advanced pharmaceutical development.

Alongside the proposed clinical trial network, the programme includes plans to establish three new NIPER institutions, upgrade seven existing institutes and strengthen the country's biopharmaceutical research and manufacturing ecosystem. [2]

These investments have implications well beyond clinical research. As new therapies become increasingly sophisticated, the infrastructure supporting their development must evolve accordingly.

More distributed clinical trials require effective coordination between research sites, laboratories, pharmaceutical manufacturers and logistics providers. Investigational medicines and biological specimens may need to travel between multiple locations, sometimes under tightly controlled handling and temperature conditions.

As India's research network expands, the development of consistent storage, transport, documentation and quality-management practices will be an important part of supporting increasingly complex studies.

The opportunity is to build these capabilities into the expanding research infrastructure from the outset, creating a foundation that can support both domestic innovation and international pharmaceutical partnerships.

An important opportunity for global clinical research

The partnership between AstraZeneca India and NIPER Raebareli is one early step in a much larger national initiative, but it provides an encouraging example of how clinical research capacity can be developed through collaboration.

By bringing together pharmaceutical expertise, academic institutions and government support, India is investing in the people, facilities and systems needed to participate more extensively in international drug development.

The potential benefits extend across the industry, from greater patient access and more diverse clinical research to the development of specialist skills and stronger regional healthcare infrastructure.

Most importantly, the expansion represents an opportunity to make high-quality clinical research accessible to more communities while strengthening India's position as a major contributor to global pharmaceutical innovation.

As the programme develops, India's growing clinical research network could become an increasingly important part of how the next generation of medicines is studied, evaluated and brought to patients.


Sources and further reading

[1] Government of India, Department of Pharmaceuticals. NIPER Raebareli and AstraZeneca India Partner to Strengthen Clinical Research Capabilities Across 25 Emerging Geographies. 14 October 2026.

https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=2323208&lang=1&reg=3

[2] Government of India, Ministry of Chemicals and Fertilisers. Budget Push to Make India a Global Biopharma Hub. 1 February 2026.

https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221492&lang=1&reg=3